About B3B

This author has not yet filled in any details.
So far B3B has created 196 entries.

Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development Symposium

The Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development symposium will be held September 11-13, 2017 at Cape Rey Resort, Carlsbad, CA. This three-day symposium with five sessions has a jam-packed agenda with case study presentations from industry leaders from Bluebird, Janssen, Pfizer and Amgen in the nonclinical development of biotherapeutics. Don’t miss out […]

July 24th, 2017|

Advancing Rare Disease Drug Discovery: Navigating the Path to an IND

Symposium Overview:

Therapies to treat rare and undiagnosed diseases are in high demand in a favorable regulatory environment. Thus, it is critically important to optimize the discovery and development of such therapies by creating – and following – the most efficient path to an investigational new drug (IND) filing. How do we do just that? […]

April 5th, 2017|

Spotlight: Every Challenge. Every Day. Every Voice.

Behind every patient stands thousands of scientists and researchers working together to develop life-saving treatments. So what happens when a patient meets the people that helped save her life?

Watch this 8-minute documentary as Ginger Tam, a lung-cancer patient, meets the researchers who worked on her cancer treatment.



March 1st, 2017|

Young Women In Bio – Inspiring girls to innovate in science


YWIB is a special initiative of Women In Bio (WIB), designed to introduce school girls to careers in science, technology, engineering and math (STEM).

YWIB creates programs and events geared towards encouraging middle and high school girls to consider the life sciences as a career […]

October 31st, 2016|

Spotlight: Charles River Laboratories Acquires Agilux Laboratories, Inc.

Charles River has announced the acquisition of Agilux Laboratories, Inc., a Worcester, Massachusetts-based contract research organization (CRO) providing a suite of integrated discovery small- and large-molecule bioanalytical services, DMPK (drug metabolism and pharmacokinetics) and pharmacology services. Agilux has built an enviable reputation for flexibility and speed, offering in vivo PK (pharmacokinetics), in vitro ADME […]

October 21st, 2016|

Spotlight: Q&A with Michael Sierra, Vice President, LEO Science & Tech Hub

Q: Can you give us a quick overview of LEO Science & Tech Hub?

The LEO Science & Tech Hub is the first dermatology-focused innovation center in Boston. The Hub will join forces with the life sciences community to advance the treatment of skin diseases. The unique structure of the Hub will allow for […]

October 3rd, 2016|

Spotlight: Q&A with Ian Chan, CEO & Founder, Abpro

About Abpro
Abpro is an integrated life science company focused on industrial biochemistry. Through its DiversImmune™ platform, Abpro leverages synthetic biology and immunology to create novel biomolecules for use in research, diagnostics, animal health and therapeutics. Abpro’s platform has been validated by major pharmaceutical, biotechnology and academic labs around the world.

What was your inspiration for […]

September 6th, 2016|

‘Bugs’ on the Subway: Monitoring Microbes in Transit

From press release of Harvard T.H. Chan School of Public Health:

“The trillions of microbes that transfer from people to surfaces could provide an early warning system for the emergence of public health threats such as a flu outbreak or a rise in antibiotic resistance, according to a study from Harvard T.H. Chan School of […]

June 30th, 2016|

Latest Startup From Harvard’s Springer Gets $51.5M

From press release:

“Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the clinic. The round was co-led by SR One and Pfizer Venture Investments, joined by Omega Funds and AbbVie Ventures. They join […]

June 30th, 2016|

Medtronic to Acquire HeartWare in $1.1B Deal

Intro of HeartWare press release:

“Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in […]

June 27th, 2016|